Boston Scientific executive discusses $533M Nalu Medical acquisition strategy and plans for peripheral nerve stimulation ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance ...

(NYSE: BSX) shares tumbled before hours today despite fourth-quarter results that topped the consensus forecast.

Over the past several years, Boston Scientific BSX has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-growth ...

Boston Scientific Corporation (NYSE:BSX) Q4 2025 Earnings Call Transcript February 4, 2026 Boston Scientific Corporation ...

We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will ...

By Kamal Choudhury Feb 4 (Reuters) - Boston Scientific on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares as ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The equity market continued ...

Fitch expects Boston Scientific to achieve double-digit top-line growth over the rating horizon, forecasting 2025 revenue of approximately $20 billion, representing roughly 20% growth compared to the ...

Delving into the details, we found 47% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $736,966, and 14 were calls, valued ...